loadpatents
Patent applications and USPTO patent grants for Silver; Phyllis.The latest application filed is for "use of il-23 and il-17 antiagonists to treat autoimmune ocular inflammatory disease".
Patent | Date |
---|---|
Use Of Il-23 And Il-17 Antiagonists To Treat Autoimmune Ocular Inflammatory Disease App 20140248279 - Cua; Daniel J. ;   et al. | 2014-09-04 |
Use Of Il-23 And Il-17 Antagonists To Treat Autoimmune Ocular Inflammatory Disease App 20130323251 - Cua; Daniel J. ;   et al. | 2013-12-05 |
Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease Grant 8,524,230 - Cua , et al. September 3, 2 | 2013-09-03 |
Use Of Il-23 And Il-17 Antagonists To Treat Autoimmune Ocular Inflammatory Disease App 20110142831 - Cua; Daniel J. ;   et al. | 2011-06-16 |
Use Of Il-23 And Il-17 Antagonists To Treat Autoimmune Ocular Inflammatory Disease App 20100111950 - Cua; Daniel J. ;   et al. | 2010-05-06 |
Use Of Il-23 And Il-17 Antagonists To Treat Autoimmune Ocular Inflammatory Disease App 20100111954 - Cua; Daniel J. ;   et al. | 2010-05-06 |
Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease App 20080199460 - Cua; Daniel J. ;   et al. | 2008-08-21 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.